|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM343618389 |
| 003 |
DE-627 |
| 005 |
20231226020852.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1111/jfd.13686
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1145.xml
|
| 035 |
|
|
|a (DE-627)NLM343618389
|
| 035 |
|
|
|a (NLM)35841600
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jia, Yi-Jun
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Antigenic epitope screening and functional modification of mannose enhance the efficacy of largemouth bass virus subunit vaccines
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.10.2022
|
| 500 |
|
|
|a Date Revised 14.10.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 John Wiley & Sons Ltd.
|
| 520 |
|
|
|a Major capsid protein (MCP) can be used as a subunit vaccine against largemouth bass virus (LMBV). However, subunit vaccines usually have low immunogenicity. Here, to identify the major immunogenicity determinant region of the MCP gene, we truncated the MCP of the LMBV gene into four parts (MCP-1, MCP-2, MCP-3 and MCP-4). Enzyme-linked immunosorbent assay (ELISA) was used to identify the antigenicity of these four truncated MCP proteins. Then, the highly antigenic truncated protein was modified with mannose and connected with functionalized single-walled carbon nanotubes (SWCNTs) as carriers. Largemouth basses were immunized by bath immersion, challenged with LMBV on the 28th day after immunization and evaluated for related immune indicators. The results indicated that the MCP-2 protein could induce a higher antibody titre than the other truncated MCP proteins. We found that the levels of immune-related genes (TNF-α, CD40, IgM, IFNγ and IL-10) in the spleen and kidney were significantly increased in the MCP-2 and MCP-2-Man groups. ELISA results showed that the antibody content in the serum increased significantly in the MCP-2 group 7 days post-vaccination and increased with days in all the vaccinated groups, with the highest observed on the 21st day. Notably, the MCP-2-Man vaccine (10 mg L-1 ) showed durability of immunoprotection efficacy that could protect largemouth basses from LMBV challenge, and the immune protection rate reached 78.94%. These results suggest that MCP-2 might be the major immunogenicity determinant region of LMBV and that the mannose-modified MCP-2 vaccine can induce stronger adaptive immune responses
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a LMBV
|
| 650 |
|
4 |
|a dominant epitopes
|
| 650 |
|
4 |
|a mannose
|
| 650 |
|
4 |
|a subunit vaccines
|
| 650 |
|
7 |
|a Capsid Proteins
|2 NLM
|
| 650 |
|
7 |
|a Epitopes
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 650 |
|
7 |
|a Nanotubes, Carbon
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a Vaccines, Subunit
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Mannose
|2 NLM
|
| 650 |
|
7 |
|a PHA4727WTP
|2 NLM
|
| 700 |
1 |
|
|a Xia, Jun-Yao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Fu-Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Guo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Bin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Journal of fish diseases
|d 1998
|g 45(2022), 11 vom: 16. Nov., Seite 1635-1643
|w (DE-627)NLM098166034
|x 1365-2761
|7 nnns
|
| 773 |
1 |
8 |
|g volume:45
|g year:2022
|g number:11
|g day:16
|g month:11
|g pages:1635-1643
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1111/jfd.13686
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 45
|j 2022
|e 11
|b 16
|c 11
|h 1635-1643
|